NYSE (USA) TSX (CANADA)

Directory of Stock Market Company

This site is a directory of Stock Market Company in USA and Canada. Each company page contains a description, stock quote, news and much more. You have also access to the best stock market game on the web.

Search into NYSE and TSX
by quote, company name or key word

facebooktwitterlinkedin
Mail

ALNY - Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing therapeutics based on ribonucleic acid interface (RNAi). The RNAi therapeutic program, ALN-RSV01, is in Phase II clinical trials for the treatment of human respiratory syncytial virus (RSV), infection. In February 2008, the Company reported the positive results from the Phase II experimental RSV infection clinical trial, referred to as the G","NYSE, Nasdaq, S&P, trading, US market, Asian market, Dow Jones, FTSE, DJIA, DAX, stocks, bonds, shares","Connect to the most current information on stocks and bonds on Reuters.com. What you need to know now about NYSE, Dow Jones, S&P, and Nasdaq at Reuters.com"

# ALNYhart

Alnylam Pharmaceuticals Inc News


6 Highly Shorted Takeover/LBO Targets Being Bought By Hedge Funds
Seeking Alpha - May 18, 2012
When a company announces that it is being taken over or acquired, its stock price usually jumps to reflect the takeover premium being paid for the company.

Arena Wins FDA Advisory Panel Backing for Obesity Pill
Proactive Investors USA & Canada - May 11, 2012
Below is a look at some of the headlines for companies that made news in the healthcare sector on May 10, 2012. Advisers to government health regulators late Thursday recommended that they approve sales of what would be the first new prescription ...

Final results from Alnylam's ALN-TTR01 Phase I trial on TTR-mediated amyloidosis
News-Medical.net - May 11, 2012
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today final results from its completed Phase I clinical trial with ALN-TTR01, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of ...

Biogen Announces US and EU Authorities Accept Oral BG-12 Marketing ...
Proactive Investors USA & Canada - May 10, 2012
Below is a look at some of the headlines for companies that made news in the healthcare sector on May 9, 2012. Biogen Idec (NASDAQ: BIIB) announced that US and EU regulatory authorities have accepted the company's marketing applications for the review ...

Alnylam Presents Final Results from a Phase I Clinical Trial of ALN-TTR01, an ...
MarketWatch (press release) - May 10, 2012
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) , a leading RNAi therapeutics company, announced today final results from its completed Phase I clinical trial with ALN-TTR01, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of ...

Alnylam Pharmaceuticals, Inc. Presents Final Results From Phase I Clinical Trial Of ALN-TTR01, An RNAi Therapeutic Targeting Transthyretin For The Treatment Of Transthyretin-Mediated Amyloidosis
Reuters Key Development - May 10, 2012

Biogen Announces US and EU Authorities Accept Oral BG-12 Marketing ...
BioMedReports (subscription) - May 10, 2012
By Staff and Wire Reports Below is a look at some of the headlines for companies that made news in the healthcare sector on May 9, 2012.

Alnylam to Webcast Presentation at Upcoming Investor Conferences
MarketWatch (press release) - May 9, 2012
CAMBRIDGE, Mass., May 09, 2012 (BUSINESS WIRE) -- Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) , a leading RNAi therapeutics company, today announced that management will present a company overview at the 11th Annual JMP Securities Research Conference ...

Biotechs Bucking The Dendreon Trap & Curse (DNDN, VRTX, VVUS, ARNA, ALNY, AMGN ...
24/7 Wall St. - May 8, 2012
When we issued our earnings previews for the week ahead, it looked as though Dendreon Corporation (NASDAQ: DNDN) had a chance of really setting the trend for the entire biotech sector this week.

JPMorgan Chase Starts Stock Coverage on Alnylam Pharma (ALNY)
Junction Report - May 8, 2012
Research analysts at JPMorgan Chase (NYSE: JPM) began coverage on shares of Alnylam Pharma (NASDAQ: ALNY) in a report released on Tuesday.

NYSE Media Coverage Selection of the best articles found in your favorit medias

Next Company >>